MRONJ Laminated Drug Card Resources

As of March 2015

  • AAOMS 2014 Update to position paper on MRONJ S. L. Ruggiero, “Diagnosis and management of Anti-Resorptive-Related Osteonecrosis of the Jaw” Gen Dent.2013 Nov-Dec
  • Damm DD, Jones DM: BP related Osteonecrosis of the Jaws Potential alternative to drug holiday Gen Dent 2013
  • Qi Wa Tang et al Risk of osteonecrosis of the jaw in cancer patients receiving denosumab:. Int Journal of Oncology 2013
  • Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. Khan AA, Morrison A, Hanley DA et al JBone Miner Res. 2015 Jan;30(1):3-23.
  • J Am Dent Assoc. 2011 Nov;142(11):1243-51.
  • Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs.
  • Hellstein JW1, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic H; “Combination of Bisphosphonates and Antiangiogenic Factors Induces Osteonecrosis of the jaw More Frequently than Bisphosphonates Alone” Oncology 2009 Christodoulou,C, et al
  • Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. Australian Endodontic Journal, vol. 35, no. 3, pp. 119–130, 2009.
  • CHMP ASSESSMENT REPORT BISPHOSPHONATES AND OSTEONECROSIS OF THE JAW European Medicines Agency, 2009
  • S. L. Ruggiero, T. B. Dodson, L. A. Assael, R. Landesberg, R. E. Marx, and B. Mehrotra, “American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw—2009 update,”
  • R. Marx DDS and colleagues: Bisphosphonate-Induced exposed Bone (Osteonecrosis/Osteoporosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment • Journal of Oral & Maxillofacial Surgery 2005
  • Ruggiero, Marx and colleagues: Practical guidelines for the Prevention, Diagnosis and Treatment of Osteonecrosis of the Jaw in Patients with Cancer • Journal of Oncology Practice Jan. 2006
  • FDA 05
  • Novartis June 2004: Expert Panel Recommendations for the Prevention, Diagnosis and Treatment of Osteonecrosis of the Jaw
  • American Academy of Oral and Maxillofacial Surgery
  • Position paper on Bisphosphonate-related Osteonecrosis of the Jaws • Sept 25, 2006 See www.aamos.org
  • American Academy of Endodontics 2006
  • Position paper Endodontic Implications of Bisphosphonate-associated Osteonecrosis of the Jaw
  • American Dental Association • Dental Management of Patients Receiving Oral Bisphosphonates
  • expert panel recommendations Aug 2006
  • Sook-Bin Woo DMD: Osteonecrosis of the Jaw and bisphosphonates NE Journal of Medicine 2005.
  • Ruggiero, Marx and colleagues: Practical guidelines for the Prevention, Diagnosis and Treatment of Osteonecrosis of the Jaw in Patients with Cancer • Journal of Oncology Practice Jan. 2006
  • Sook-Bin Woo DMD: Systemic review: Bisphosphonates and Osteonecrosis of the Jaws
  • Annals of Internal Medicine May 2006
  • Mayo Clinic: Consensus statement for the Use of Bisphosphonates in Multiple Myeloma. August 2006
  • Bisphosphonate Related Osteonecrosis of the Jaw-An Update on Clinical , Pathological and Management aspects. • Journal of Head and Neck Pathology Dec, 2007 Ficarra & Beninati